PRESENTATION OBJECTIVES:
1. Describe the differences between mastocytosis and hereditary alphatryptasemia
2. Use tryptase calculations in the evaluation of mast cell activation
3. Describe the evidence based approach to mast cell activation syndrome management

DISCLOSURES:

Speaker:
• Regeneron/Sanofi
• AstraZeneca
• Amgen
• Optinose
• GSK
• Blueprint
• Genentech

Advisory Board Member:
• Optinose